BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 524 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,512,608 | -17.5% | 22,221 | -1.1% | 0.98% | -11.7% |
| Q2 2023 | $1,834,258 | +39.7% | 22,470 | +27.0% | 1.11% | +32.4% |
| Q1 2023 | $1,312,805 | -9.3% | 17,695 | +1.3% | 0.84% | -17.2% |
| Q4 2022 | $1,448,070 | +13.7% | 17,472 | +289.3% | 1.01% | +10.4% |
| Q3 2022 | $1,274,000 | -16.2% | 4,488 | +2.3% | 0.92% | -15.4% |
| Q2 2022 | $1,521,000 | -20.5% | 4,387 | -0.7% | 1.08% | -10.5% |
| Q1 2022 | $1,914,000 | -15.4% | 4,420 | +1.1% | 1.21% | -9.8% |
| Q4 2021 | $2,262,000 | -7.9% | 4,372 | -13.7% | 1.34% | -15.8% |
| Q3 2021 | $2,455,000 | +9.2% | 5,067 | +1.5% | 1.59% | +4.2% |
| Q2 2021 | $2,249,000 | +3.3% | 4,994 | -12.4% | 1.53% | -5.0% |
| Q1 2021 | $2,177,000 | +22.6% | 5,701 | +1.9% | 1.61% | +13.6% |
| Q4 2020 | $1,775,000 | +28.3% | 5,592 | +0.1% | 1.42% | +11.2% |
| Q3 2020 | $1,384,000 | -5.1% | 5,589 | +1.2% | 1.27% | -11.9% |
| Q2 2020 | $1,458,000 | +8.1% | 5,524 | -22.3% | 1.44% | -10.8% |
| Q1 2020 | $1,348,594 | -9.2% | 7,112 | +5.1% | 1.62% | +13.0% |
| Q4 2019 | $1,485,000 | – | 6,768 | – | 1.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |